Sphingosine-1-phosphate receptor 1 modulator Pregnancy: Contraindicated during pregnancy and in women of childbearing potential not using effective contraception. A negative pregnancy test is required before initiation and women must be counselled on the serious risk to the foetus; effective contraception is required during treatment and for approximately 1 week after stopping (time to eliminate ponesimod). If a woman becomes pregnant during treatment, ponesimod must be discontinued immediately. Should not be used during breast-feeding (section 4.6).

Ponesimod

Brand names: Ponvory

Ponesimod is an oral, selective sphingosine-1-phosphate receptor 1 (S1P1) modulator used to treat relapsing forms of multiple sclerosis in adults with active disease.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Maintenance 20 mg once daily, started only after a mandatory 14-day titration: days 1 and 2 — 2 mg; days 3 and 4 — 3 mg; days 5 and 6 — 4 mg; day 7 — 5 mg; day 8 — 6 mg; day 9 — 7 mg; day 10 — 8 mg; day 11 — 9 mg; days 12, 13 and 14 — 10 mg

Route: Oral (film-coated tablets; may be taken with or without food)

Frequency: Once daily

Treatment must be started with the 14-day treatment initiation pack and initiated under the supervision of a physician experienced in the management of multiple sclerosis. Re-initiation after interruption during titration or maintenance: if fewer than 4 consecutive doses are missed, resume treatment with the first missed dose; if 4 or more consecutive doses are missed, reinitiate at day 1 (2 mg) of the titration regimen with a new initiation pack, and repeat the same first-dose monitoring as at treatment initiation. Obtain an ECG in all patients before initiation. First-dose 4-hour monitoring is recommended for patients with sinus bradycardia (heart rate below 55 bpm), first- or second-degree (Mobitz type I) AV block, or a history of myocardial infarction or heart failure occurring more than 6 months before initiation and now stable; monitor hourly pulse and blood pressure and obtain an ECG at the end of the 4 hours. Beta-blockers: if resting heart rate on chronic beta-blocker therapy is greater than 55 bpm, ponesimod can be introduced; if it is 55 bpm or less, interrupt the beta-blocker until baseline heart rate exceeds 55 bpm, then start ponesimod and reintroduce the beta-blocker once ponesimod is up-titrated to the maintenance dose. Elderly (65 years and over): prescribe with caution — not included in clinical studies. Hepatic impairment: no adjustment in mild impairment (Child-Pugh A); contraindicated in moderate and severe impairment (Child-Pugh B and C). Paediatric: safety and efficacy in patients under 18 years have not been established and no data are available.

Dose adjustments

Renal

No dose adjustment is needed in patients with mild to severe renal impairment (section 4.2).

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to the active substance or to any of the excipients
Immunodeficient state
Myocardial infarction, unstable angina, stroke, transient ischaemic attack, decompensated heart failure requiring hospitalisation, or NYHA Class III or IV heart failure in the last 6 months
Mobitz type II second-degree or third-degree AV block, or sick sinus syndrome, unless the patient has a functioning pacemaker
Severe active infections or active chronic infections
Active malignancies
Moderate or severe hepatic impairment (Child-Pugh class B and C)
Pregnancy, and women of childbearing potential not using effective contraception

Side effects

Nasopharyngitis (19.7%) and upper respiratory tract infection (11%) — very common
Alanine aminotransferase increased (17.9%) — very common; AST, hepatic enzyme and transaminase increases (common)
Lymphopenia and decreased lymphocyte count (common)
Hypertension (common)
Bradycardia (common) and transient AV conduction delay at initiation; macular oedema (common)
Dizziness, hypoaesthesia, somnolence, migraine, seizure (common); dyspnoea and cough (common)

Interactions

Beta-blockers and other drugs that lower heart rate or slow AV conduction — additive heart-rate-lowering effect; determine whether the patient is taking such drugs before initiation and consider temporary interruption of the beta-blocker (eMC section 4.4)
Class Ia (e.g. quinidine, procainamide) and Class III (e.g. amiodarone, sotalol) antiarrhythmics and other QT-prolonging drugs — not studied with ponesimod; associated with torsades de pointes in patients with bradycardia — seek cardiology advice (openFDA section 7.2)
Anti-neoplastic, immunosuppressive or immune-modulating therapies — risk of additive immune effects during and in the weeks after treatment; initiating ponesimod after alemtuzumab is not recommended; ponesimod can generally be started immediately after beta interferon or glatiramer acetate (openFDA section 7.1)
Live attenuated vaccines — avoid during treatment and for 1 to 2 weeks afterwards; if required, give at least 1 month before initiation, and test for varicella zoster virus antibodies and vaccinate antibody-negative patients before starting (openFDA sections 7.4 and 2.1)
Note: the eMC section 4.5 text was not captured in the fetched source — verify the full UK interaction list against the current SPC

Clinical monograph

How it works

It selectively binds the S1P1 receptor on lymphocytes, retaining them in lymphoid tissue and reducing the circulating lymphocytes that drive central nervous system inflammation.

Prescribing in practice

It can cause a transient fall in heart rate and AV conduction delay at initiation, so a gradual up-titration starter pack is used and cardiac assessment is needed where heart disease is present.
Baseline checks should include full blood count, liver function, varicella-zoster immunity, blood pressure and ophthalmic review for macular oedema risk.
Missing several consecutive doses requires restarting with the titration regimen, and live vaccines should be avoided during and after treatment.

Monitoring

Monitor full blood count, liver function, blood pressure, and for infection, breathlessness, or visual disturbance during therapy.

Counselling the patient

Do not miss doses; if you stop for several days you may need to restart with the gradual build-up pack.
Report any breathlessness, palpitations, visual changes, or signs of infection.
Avoid live vaccines and tell your team if you are planning a pregnancy.

Evidence & guidelines

The OPTIMUM trial showed lower annualised relapse rates versus teriflunomide, and NICE recommends it as an option for active relapsing-remitting MS.

Reference: NICE TA767; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways